Co-Diagnostics Earnings Reports

Co-Diagnostics reported a net loss of $7.7 million in Q2 2025 as revenue dropped to $0.16 million due to the lack of grant revenue. Operating expenses were reduced year-over-year, but the company continues to invest in its Co-Dx PCR platform.

Co-Diagnostics reported a significant decrease in revenue for Q1 2025, primarily due to the timing of grant revenue recognition, with total revenue at $0.1 million. Despite this, the company managed to reduce its operating expenses and net loss compared to the prior year, while maintaining a healthy cash position.

In Q4 2024, Co-Diagnostics generated $149,330 in revenue and posted an adjusted EPS of -$0.36. The company remained pre-commercial with limited product activity and continued development of its diagnostic platform.

Co-Diagnostics announced their Q3 2024 financial results, highlighting progress in their pipeline development and ongoing dialogue with the FDA regarding their 510(k) application.

Co-Diagnostics reported their financial results for the second quarter of 2024, highlighting the progress made, including the 510(k) application submission to the FDA for their new instrument and COVID-19 test kit for over-the-counter use.

Co-Diagnostics announced its first quarter financial results, highlighting progress with new manufacturing facilities and plans for FDA submissions and test development.

Co-Diagnostics reported progress towards strategic goals in Q4, including an Emergency Use Authorization submission to the FDA for their Co-Dx PCR Pro™ instrument, mobile app, and COVID-19 test. The company is also expanding production capacity and developing new tests.

Co-Diagnostics reported total revenue of approximately $2.5 million in the third quarter of 2023, including $2.3 million in grant revenue. The company is progressing in the development of other test indications beyond Covid-19 for the new platform: TB, multiplex respiratory, and HPV.

Co-Diagnostics reported its Q2 2023 financial results, noting a decline in COVID diagnostic kit sales but highlighted progress in expanding their PCR technology and advancements towards the FDA submission of the Co-Dx PCR Home platform.

Co-Diagnostics reported a decline in financial performance due to decreased COVID-related sales. However, they continued to advance their longer-term strategy, particularly with the Co-Dx PCR Home™ platform, and received grant awards.

Co-Diagnostics reported full year 2022 financial results, impacted by decreased demand for COVID-19 testing. The company is focusing on its Co-Dx PCR Home™ platform and its potential beyond COVID-19.

Co-Diagnostics reported lower third-quarter results due to decreased demand for their COVID-19 tests, but made substantial progress on their Co-Dx PCR Home™ platform, which is nearing its final stages and expects clinical trials to begin soon. The company's ability to generate positive cash flow supported further development and optimization efforts for their Co-Dx PCR Home platform.

Co-Diagnostics reported lower volumes for its Logix Smart™ COVID-19 Test in the second quarter, attributed to a reduction in mandated testing and government funding. The company is focusing on growing its international distributor network, expanding its infectious disease testing menu, and developing its at-home/point-of-care testing platform.

Co-Diagnostics reported a strong first quarter in 2022, achieving record revenue of $22.7 million and a diluted EPS of $0.34.

Co-Diagnostics reported record full year 2021 revenue of $97.9 million. The company highlighted its strengthened executive management team and advancements in its at-home/point-of-care diagnostics platform.

Co-Diagnostics reported strong Q3 2021 financial results, achieving record revenue of $30.1 million and a fully diluted EPS of $0.38. The company is optimistic about its upcoming point of care/at-home diagnostic platform and its potential impact on infectious disease diagnostics.

Co-Diagnostics reported a strong second quarter with revenue of $27.4 million, pre-tax income of $11.9 million, and diluted EPS of $0.33. The company is focused on delivering high-quality diagnostic testing kits and is positioned for future growth with investments in talent and R&D.

Co-Diagnostics reported a strong first quarter in 2021, with revenue reaching $20.0 million and diluted EPS of $0.26. The company is focused on developing rapid PCR diagnostic testing and expanding its product portfolio to meet global demand.

Co-Diagnostics reported record fourth-quarter results, driven by demand for its Logix Smart COVID-19 Test. Revenue reached $27.1 million, and pre-tax income was $15.8 million.

Co-Diagnostics announced financial results for the third quarter ended September 30, 2020, reporting widespread uptake of their COVID-19 test domestically and abroad. The company also received CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests.

Co-Diagnostics reported strong Q1 2020 results driven by robust sales of COVID-19 tests and achieved net profitability through the middle of the second quarter of 2020.